Clinical Trial Update: Effect of 13-Week Treatment With Vildagliptin as Add-On Therapy to Improve Glucose Variability in Type II Diabetes [Phase 4]

View source ↗

Summary

A Phase 4 trial assessing 13 weeks of add-on vildagliptin to improve glucose variability in type 2 diabetes, trial terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Vildagliptin (vildagliptin)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Type 2 Diabetes Mellitus | Phase 4 | Status: TERMINATED